The opioid pharmacological profile ofcis-(-)-N-normetazocine derivatives is deeply affected by the nature of theirN-substituents. Here, our efforts were focused on the synthesis and pharmacological evaluation of novel derivatives of the lead LP1, a multitarget opioid analgesic compound featuring anN-phenylpropanamido substituent. LP1 derivatives5a-dand6a-dwere characterized by flexible groups at theN-substituent that allow them to reposition themselves relative tocis-(-)-N-normetazocine nucleus, thus producing different pharmacological profiles at the mu, delta and kappa opioid receptors (MOR, DOR and KOR) in in vitro and in vivo assays. Among the series, compound5c, with the best in vitro and in vivo profile, resulted a MOR agonist which displays a KiMORof 6.1 nM in a competitive binding assay, and an IC50value of 11.5 nM and an Imaxof 72% in measurement of cAMP accumulation in HEK293 cells stably expressing MOR, with a slight lower efficacy than LP1. Moreover, in a mouse model of acute thermal nociception, compound5c,intraperitoneally administered, exhibits naloxone-reversed antinociceptive properties with an ED50of 4.33 mg/kg. These results expand our understanding of the importance ofN-substituent structural variations in the opioid receptor profile ofcis-(-)-N-normetazocine derivatives and identify a new MOR agonist useful for the development of novel opioid analgesics for pain treatment.

Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists

Turnaturi Rita
Primo
;
Parenti Carmela;Marrazzo Agostino;Amata Emanuele;Pasquinucci Lorella
Ultimo
2018

Abstract

The opioid pharmacological profile ofcis-(-)-N-normetazocine derivatives is deeply affected by the nature of theirN-substituents. Here, our efforts were focused on the synthesis and pharmacological evaluation of novel derivatives of the lead LP1, a multitarget opioid analgesic compound featuring anN-phenylpropanamido substituent. LP1 derivatives5a-dand6a-dwere characterized by flexible groups at theN-substituent that allow them to reposition themselves relative tocis-(-)-N-normetazocine nucleus, thus producing different pharmacological profiles at the mu, delta and kappa opioid receptors (MOR, DOR and KOR) in in vitro and in vivo assays. Among the series, compound5c, with the best in vitro and in vivo profile, resulted a MOR agonist which displays a KiMORof 6.1 nM in a competitive binding assay, and an IC50value of 11.5 nM and an Imaxof 72% in measurement of cAMP accumulation in HEK293 cells stably expressing MOR, with a slight lower efficacy than LP1. Moreover, in a mouse model of acute thermal nociception, compound5c,intraperitoneally administered, exhibits naloxone-reversed antinociceptive properties with an ED50of 4.33 mg/kg. These results expand our understanding of the importance ofN-substituent structural variations in the opioid receptor profile ofcis-(-)-N-normetazocine derivatives and identify a new MOR agonist useful for the development of novel opioid analgesics for pain treatment.
6,7-benzomorphan derivatives; MOR agonist; cAMP accumulation assay; pain; radioligand competitive binding; tail-flick test
File in questo prodotto:
File Dimensione Formato  
molecules-23-00677 (1).pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/325612
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact